Bristol-Myers Squibb Co. Watch

from 8-K 55 pages Underwriting Agreement, Dated as of February 14, 2024 Bristol-Myers Squibb Company

from 8-K 41 pages Underwriting Agreement, Dated as of October 30, 2023 Bristol-Myers Squibb Company $1,000,000,000 5.750% Notes Due 2031 $1,000,000,000 5.900% Notes Due 2033 $1,250,000,000 6.250% Notes Due 2053 $1,250,000,000 6.400% Notes Due 2063

from 8-K 37 pages Underwriting Agreement, Dated as of February 15, 2022 Bristol-Myers Squibb Company $1,750,000,000 2.950% Notes Due 2032 $1,250,000,000 3.550% Notes Due 2042 $2,000,000,000 3.700% Notes Due 2052 $1,000,000,000 3.900% Notes Due 2062

from 8-K 33 pages Underwriting Agreement, Dated as of November 9, 2020 Bristol-Myers Squibb Company $1,500,000,000 0.537% Notes Due 2023 $1,000,000,000 0.750% Notes Due 2025 $1,000,000,000 1.125% Notes Due 2027 $1,250,000,000 1.450% Notes Due 2030 $750,000,000 2.350% Notes Due 2040 $1,500,000,000 2.550% Notes Due 2050

from 8-K 32 pages Bristol-Myers Squibb Company $750,000,000 Senior Floating Rate Notes Due 2020 $1,000,000,000 2.550% Senior Notes Due 2021 $500,000,000 Senior Floating Rate Notes Due 2022 $1,500,000,000 2.600% Senior Notes Due 2022 $3,250,000,000 2.900% Senior Notes Due 2024 $2,250,000,000 3.200% Senior Notes Due 2026 $4,000,000,000 3.400% Senior Notes Due 2029 $2,000,000,000 4.125% Senior Notes Due 2039 $3,750,000,000 4.250% Senior Notes Due 2049 Purchase Agreement May 7, 2019

from 8-K 21 pages Underwriting Agreement, Dated as of February 22, 2017 Bristol-Myers Squibb Company 1.600% Notes Due 2019 3.250% Notes Due 2027

from 8-K 37 pages Underwriting Agreement, Dated as of April 29, 2015 Bristol-Myers Squibb Company 1.000% Notes Due 2025 1.750% Notes Due 2035

from 8-K 37 pages Underwriting Agreement, Dated as of October 24, 2013 Bristol-Myers Squibb Company 1.750% Notes Due 2019 3.250% Notes Due 2023 4.500% Notes Due 2044

from 8-K 36 pages Bristol-Myers Squibb Company 0.875% Notes Due 2017 2.000% Notes Due 2022 3.250% Notes Due 2042 Underwriting Agreement

from SC 13D/A 1 page Joint Filing Agreement

from 8-K 39 pages Bristol-Myers Squibb Company 5.450% Notes Due 2018 6.125% Notes Due 2038 Underwriting Agreement

from 8-K 39 pages Bristol-Myers Squibb Company 5.875% Notes Due 2036 Underwriting Agreement

from SC 13G/A 1 page Bristol-Myers Squibb Pharma Company (Formerly Dupont Pharmaceuticals Company), a Delaware General Partnership and Wholly-Owned Subsidiary of Bristol-Myers Squibb Company, Acquired the Securities Being Reported on in This Schedule 13g/a Upon the Consummation of the Acquisition of Dupont Pharmaceuticals Company by Bristol-Myers Squibb Company on October 1, 2001. the Sole Partners of Bristol-Myers Squibb Pharma Company Are Bristol-Myers Squibb Pharma Holding Company, L.L.C. and E. R. Squibb & Sons, L.L.C. E. R. Squibb & Sons, L.L.C. Owns All of the Outstanding Stock of Bristol-Myers Squibb Pharma Holding Company, L.L.C. Bristol-Myers Squibb Company Owns All of the Outstanding Stock of E. R. Squibb & Sons, L.L.C

from S-3/A ~50 pages Underwriting agreement

from S-3/A ~50 pages Underwriting agreement

from S-3 ~20 pages Underwriting Agreement